CRISPR Therapeutics Balance Sheet Health
Financial Health criteria checks 5/6
CRISPR Therapeutics has a total shareholder equity of $1.9B and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $2.2B and $346.8M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
Interest coverage ratio | n/a |
Cash | US$1.69b |
Equity | US$1.88b |
Total liabilities | US$346.77m |
Total assets | US$2.23b |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: C2RS34's short term assets ($1.9B) exceed its short term liabilities ($108.8M).
Long Term Liabilities: C2RS34's short term assets ($1.9B) exceed its long term liabilities ($238.0M).
Debt to Equity History and Analysis
Debt Level: C2RS34 is debt free.
Reducing Debt: C2RS34 had no debt 5 years ago.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: C2RS34 has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if C2RS34 has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.